Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guidelines in Oncology/NCCN Guidelines for Acute Myeloid Leukemia/AML to include Revuforj (revumenib). Revumenib received a Category 2A recommendation for the treatment of relapsed or refractory (R/R) AML with an NPM1 mutation/mNPM1. This update was based on positive pivotal re ...